Skip to main content

Table 2 Causative organisms and antimicrobial management on OPAT

From: Outpatient parenteral antimicrobial therapy (OPAT) for aortic vascular graft infection; a five-year retrospective evaluation

Patient No. Organism(s) Cultured Antimicrobial therapy 1 Antimicrobial 2 (switch reason) Antimicrobial 3 (switch reason) Antimicrobial 4 (switch reason) Oral suppression
1 Bacteroides fragilis (blood culture) Ertapenem + metronidazole (OPAT, 6 weeks) PO Moxifloxacin (oral consolidation)    Co-trimoxazole, RIP on suppression
2 Salmonella enteritidis, Streptococcus anginosis (blood culture, sac aspirate) Ceftriaxone, 6 weeks PO Co-trimoxazole (oral consolidation)    Co-trimoxazole
3 None Ertapenem+ daptomycin, 6 weeks PO cefuroxime (oral consolidation)    Co-trimoxazole
4 None Ertapenem + daptomycin, 8 weeks PO Linezolid + cefixime (oral consolidation) Ertapenem and daptomycin (rising inflam markers) PO Linezolid + cefuroxime Cefuroxime
5 CoNS, (sac aspirate) Piperacillin- Tazobactam + daptomycin Teicoplanin +linezolid (admitted for graft reposition, unclear reason for antibiotic change) Piperacillin- Tazobactam + daptomycin, 6 weeks PO Ciprofloxacin +metronidazole (oral consolidation) Co-trimoxazole, RIP on suppression
6 None Co- Amoxiclav IV, 6 weeks Cefuroxime PO (oral consolidation)    Amoxicillin
7 None Co-amoxiclav IV, 6 weeks Co-amoxiclav PO (oral consolidation, 6 months)    None
8 Enterococcus faecalis, Bacteroides caccae (vertebral biopsy) Ertapenem+metronidazole, 8 weeks Meropenema + caspofungina + PO linezolid (deterioration and pain) Meropenema, PO fluconazole (anaemia on linezolid and caspofungin)   Co-amoxiclav + Fluconazole
9 Pseudomonas (sac aspirate, blood culture) Piperacillin-tazobactam + IV/PO ciprofloxacin on and off × 1 year, on OPAT between multiple temporising measures Piperacillin-tazobactam + daptomycin (added for pneumonia) Vancomycin (admitted with pneumonitis on daptomycin) + meropenem (later rash on piperacillin-tazobactam) PO Ciprofloxacin + PO co-amoxiclav (oral suppression) Ciprofloxacin + co-amoxiclav
10 MSSA, Pseudomonas aeruginosa, anaerobes, CoNS, Enterococcal sp. (VRE) – (sinus swabs/excision) Piperacillin-tazobactam + PO rifampicin, 12 weeks PO Ciprofloxacin (oral consolidation, 1 year) Meropenem + daptomycin (re-treatment 2 years later) Ertapenem + daptomycin (OPAT, 6 months) Ciprofloxacin
11 Staphylococcus caprae, candida (excised sinus) Piperacillin-tazobactam, 12 weeks PO co-amoxiclav (oral consolidation) Daptomycin (admitted with pneumonia) Vancomycin (eosinophilia on daptomycin) RIP 5 months, inpatient on IV antibiotics for pneumonia
  1. IV Intravenous, PO Oral
  2. aself-compounded and administered